biosurfit, a rapidly-growing company focused on the Point of Care medical diagnostic market, is pleased to announce today the appointment of Mr. Gordon Powell as an Advisory Board Member.

 

Mr. Gordon Powell brings with him over 20 years of sales and marketing experience in the global in-vitro diagnostics industry. Most recently Gordon was the Group Marketing Director at Axis-Shield based in London and before then he was Marketing Director for the launch of the Afinion™ point of care system in the United States and was based at the Axis-Shield office in Boston. Gordon is currently based in Glasgow, UK and is the CEO of Qnostics Ltd. who are a leading provider of controls for the molecular diagnostics industry. He holds a Post Graduate Diploma in Marketing and is a member of the Chartered Institute of Marketing.

 

Commenting on his appointment, Gordon Powell said: “I am delighted to be able to take up this appointment with biosurfit at such an important time in their development. biosurfit is already widely respected and recognized for their innovative point of care technology and I am delighted to be able to advise on their launch strategy going forward. I am proud to take on this role and am looking forward to working with the rest of the team.”

 

Daniel Neves, Co-founder and CMO of biosurfit, commented, “We are delighted to have Gordon working with us. His experience and network in the IVD and especially in the POC industry will be of a great value as we continue to implement our Go-to-market strategy. It’s never been more important for us to hear from experience and our hope is that it will enable us to make smarter choices in our coverage of the market.”

 

About biosurfit
biosurfit is a Venture Capital backed diagnostics company founded in 2006. The company invented and developed breakthrough technologies that enable fast, precise and affordable blood analysis, aiming for the key parameters that doctors really want. These proprietary technologies are combined in the spinit® instrument, using a user-friendly reader and disposable disk cartridges for specific clinical conditions. The spinit® instrument uses only one drop of blood to delivers precise results within 10-15 minutes. Initial disposable cartridges to be launched in 2013 include CRP, Blood Count and an Inflammation Panel. It is planned that future tests will include diabetes and cardiac multi-parameter panels.

 

For more information, please contact:

 

Daniel Neves, CMO of biosurfit, phone: +351 217500228